INTRODUCTION {#s1}
============

Aneuploidy is common in solid tumors, with nearly 90% of such tumors being aneuploid \[[@R1]\]. Despite the prevalence of aneuploidy in these cancers, it has not been firmly established if aneuploidy is an early step that drives malignant transformation, results as a consequence of transformation, or what role, if any, oncogenes play in this process. Although many solid tumors are characterized by a specific oncogenic mutation, very few reports examined the role that the resulting oncoprotein plays in driving the initial stages of tumor development, possibly through the acquisition of aneuploidy and in overcoming aneuploidy-dependent growth arrest. In many of these reports, oncogene-induced aneuploidy results from the overexpression of a protein that is central to the chromosome segregation machinery or regulates the process of chromosome segregation \[[@R2]--[@R6]\]. Although one report demonstrates that an oncogenic transcription factor, *TLX1*, is sufficient to induce aneuploidy in T-cell progenitors, the process involves a limited mechanism in which specific genes important for maintaining mitotic checkpoint control are affected \[[@R7]\].

Upon the acquisition of aneuploidy, a cell\'s natural response is to attenuate proliferation. Previous work demonstrated that the induction of aneuploidy in diploid or near diploid cell lines resulted in significant proliferative defects \[[@R8], [@R9]\], raising an apparent contradiction for tumor progression: rapidly proliferating tumor cells are often aneuploid, a state that under normal circumstances is not conducive to proliferation \[[@R10]\]. Therefore, tumor cells must develop a mechanism to overcome aneuploid-dependent proliferative defects and develop an enhanced proliferation rate. However, the mechanism by which an oncogene promotes aneuploidy in pre-cancerous cells, how these cells overcome the adverse proliferative effects associated with this state, and whether post-translational modifications can regulate this process are important, yet unanswered, questions in the development of solid tumors.

Like other solid tumors, aneuploidy is common in Rhabdomyosarcoma (RMS) \[[@R11]\], which accounts for nearly half of childhood soft tissue sarcomas. RMS is comprised of two main subtypes: embryonal (ERMS) and alveolar (ARMS), each defined by its unique histology, clinical presentation, therapy, and prognosis \[[@R12]\]. ARMS, the more aggressive subtype, is primarily defined by the t(2;13)(q35;q14) translocation, which creates the oncogenic fusion protein PAX3-FOXO1 \[[@R13], [@R14]\]. In addition to the defining cytogenetic abnormality, ARMS tumor cells contain cytogenetic evidence of polyploidy, having cells ranging in chromosome number from hypodiploid to hypertetraploid, with a wide and heterogeneous range of chromosome number in cells within a single patient sample \[[@R11], [@R15]--[@R18]\]. There were also instances of chromosome amplification as double minutes and heterogeneously staining regions, gains and losses through insertions and deletions, derivative chromosomes and additional translocations, and breakpoints around the centromere \[[@R11], [@R15]--[@R18]\]. Despite extensive work understanding the altered molecular characteristics of PAX3-FOXO1 relative to PAX3 \[[@R19]--[@R25]\] and the knowledge that phosphorylation of the fusion protein contributes to ARMS tumor phenotypes \[[@R26]\], it is not known what role, if any, the fusion protein plays in the promotion of aneuploidy and chromosomal structural abnormalities, overcoming aneuploidy-dependent proliferative defects, and whether phosphorylation of the fusion protein contributes to this process.

In this study we examine how the expression of PAX3-FOXO1 affects global mRNA and miRNA expression. We are the first to show that the presence of PAX3-FOXO1 is sufficient to alter mRNA and miRNA expression, either through direct regulation of genes or indirectly through downstream effects, subsequently altering protein levels important for multiple aspects of chromosome number and structure, thereby promoting the aneuploid state. Further, we are the first to demonstrate that the presence of an oncogene is sufficient to alter, either directly or indirectly, the expression of multiple growth related mRNA and miRNA to overcome aneuploidy-induced proliferative defects. In addition, inhibition of phosphorylation at Ser201 or Ser205 on PAX3-FOXO1 reversed oncogene dependent mRNA and miRNA changes, and inhibited the proliferation of cells containing chromosomal abnormalities. Our results allow us to propose a model by which the expression and phosphorylation of an oncogene, PAX3-FOXO1, serves as the driving molecular event to initiate the development of a solid tumor by reprograming cells to induce aneuploidy and override aneuploidy-induced growth arrest.

RESULTS {#s2}
=======

PAX3-FOXO1 is sufficient to alter the expression of mRNA and miRNA to promote aneuploidy {#s2_1}
----------------------------------------------------------------------------------------

To understand how PAX3-FOXO1 affects global mRNA and microRNA (miRNA) expression, we stably transduced passage-matched mouse primary myoblasts with the MSCV-IRES-puromycin retroviral vector (negative control), or the same retroviral vector expressing FLAG-epitope tagged PAX3 (FLAG-PAX3), or FLAG-PAX3-FOXO1 (Figure [1A](#F1){ref-type="fig"}), a tag previously shown to not affect Pax3 or Pax3-FOXO1 function \[[@R24], [@R26]\]. The transduced cells were selected with puromycin; selected cells were harvested from three independent transductions and pooled, resulting in a single mixed population for each individual construct. By utilizing a population of transduced cells, we remove the potential for variability that may occur from clonal effects. The level of PAX3-FOXO1 expression we observed is equivalent to the level of expression of the fusion protein in ARMS tumor cell lines ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"} and \[[@R27], [@R28]\]) and is therefore directly relevant to the role of the oncogenic fusion protein in ARMS. This model allows us to use a physiologically relevant cell system to determine how the sole expression of the oncogenic PAX3-FOXO1 can initiate a cascade of events, both direct and downstream, over a series of proliferation events, to contribute to the initial stages of tumor development with respect to aneuploidy and overcoming aneuploidy-dependent proliferative defects. This model is in direct contrast to tumor cell lines or primary tumor samples in which it is difficult to determine whether these processes result as a "byproduct" of the final oncogenic state.

![The expression of PAX3-FOXO1 promotes aneuploidy and chromosomal structural abnormalities\
Expression of **A.** PAX3, PAX3-FOXO1 or **B.** PAX3-FOXO1 phosphomutants. Total extracts were made from stably transduced cells and protein was determined using an antibody specific for PAX3, as described in the Materials and Methods. Representative picture of a metaphase chromosome analysis for **C.** cells stably transduced with empty vector, PAX3 or PAX3-FOXO1 or **D.** individual PAX3-FOXO1 phosphomutants. The closed arrows indicate representative sister chromatid dissociation, the open arrow indicate representative telomere association, and the dotted arrow indicate a representative double minute.](oncotarget-07-62814-g001){#F1}

We performed mRNA and miRNA deep sequencing on total RNA isolated from three independent growths of stably transduced primary myoblasts and utilized the resulting sequencing data in large-scale comparative transcriptomic analyses, using the on-line Galaxy program or miRNAKey, respectively (see Materials and Methods). Since all stable lines were generated simultaneously and with identical methods, any artifactual effects of the process on mRNA and miRNA expression would be expected to be present in all samples and would therefore by corrected for by our differential analysis. The data used for subsequent studies were limited to 1) mRNA or miRNA displaying statistically significant differences (p \< 0.05), 2) mRNA or miRNA present in both data sets being analyzed to rule out artifactual differences resulting from depth of read, and 3) mRNA or miRNA that exhibited at least 2-fold difference in expression either up- or downregulated. Finally, the biological functions of the differentially expressed mRNA or target genes of miRNA were categorized using the Onto-Express gene ontology software (<http://vortex.cs.wayne.edu/projects.htm>).

We found that in total PAX3-FOXO1 altered the expression of 846 genes, with 562 being upregulated and 284 being downregulated, relative to cells expressing wild-type PAX3 (data not shown). Fifty-nine of these differentially expressed genes have biological functions directly involved with multiple processes important for maintaining chromosome number and structure (Table [1](#T1){ref-type="table"}) with 48/59 of these genes being downregulated. The affected genes include kinases that regulate chromosome separation and mitotic progression, cohesins, centromeric proteins, regulators of cytokinesis, components or regulators of the condensin complex, proteins involved with chromosomal segregation, and components of the mitotic spindle. Finally, six of the 59 genes that specifically contribute to promoting aneuploidy contain PAX3-FOXO1 binding sites in their proximal promoters, as previously described \[[@R29]\] (Table [1](#T1){ref-type="table"}, carat) and six of these genes have altered gene expression levels consistent with changes seen in human tumor samples \[[@R30]--[@R33]\] (Table [1](#T1){ref-type="table"}, pound sign).

###### Differentially expressed mRNA important for promoting aneuploidy by altering genes important for chromosome segregation/cytokinesis, chromosome cohesion/condensing, and mitotic progression

  PROMOTION OF ANEUPLOIDY                                                                                      
  --------------------------------------------- ---------------------------------------------- ------- ------- -------
  ***Chromosome Segregation/Cytokinesis***                                                                     
  ANLN                                          Required for cytokinesis                       −2.33   −4.21   +1.89
  AURKA                                         Regulate chromosome segregation                −2.29   −2.76   
  AURKB                                         Regulate chromosome segregation                        −5.13   
  [^\#^](#tfn_002){ref-type="table-fn"}CENPF    Centrosome segregation                                 −2.71   
  CDC25B                                        Required for abscission in cytokinesis         +2.20           
  CORO1C                                        Involved in cytokinesis                        −2.27   −2.01   
  ECT2                                          Nucleotide exchange factor - cytokinesis               −2.88   
  ESPL1                                         Protease in chromosome segregation                     −4.01   
  [^\^^](#tfn_002){ref-type="table-fn"}KLHL13   Chromosome segregation                                 +2.25   
  MYH10                                         Involved in cytokinesis                        −2.09   −4.58   
  Pard6g                                        Cell division and cell polarization                    −3.06   
  PRC1                                          Regulator of cytokinesis                               −2.09   
  PSRC1                                         Required for normal chromosome segregation     −2.28   −4.15   
  ***Chromosome Cohesion/Condensing***                                                                         
  CDC20B                                        Destruction of condensins                              −2.71   
  [^\^^](#tfn_002){ref-type="table-fn"}CEP250   Centriole cohesion - chromosome segregation            −2.57   
  NCAPD2                                        Regulatory subunit of condensin complex                −2.09   
  NCAPG2                                        Subunit of condensin complex                           −2.72   
  NCAPH                                         Subunit of condensin complex                           −3.56   
  PDS5B                                         Regulator of cohesin                                   −2.18   
  [^\#^](#tfn_003){ref-type="table-fn"}RCC1     Regulator of chromosome condensation                   −2.27   
  [^\^^](#tfn_002){ref-type="table-fn"}SGOL1    Involved with chromosome cohesion                      −5.88   +2.76
  SGOL2                                         Prevents premature release of cohesin                  −3.41   
  SMC2                                          Critical for mitotic chromosome condensation           −3.10   
  ***Mitotic Progression***                                                                                    
  BUB1                                          Mitotic checkpoint kinase                              −4.71   
  BUB1B                                         Spindle checkpoint kinase                              −4.04   
  CCNA2                                         Cyclin -- regulate G2/M progression                    −2.44   
  CCNG1                                         Cyclin -- regulate G2/M checkpoint             −2.19   −2.66   
  CDK1                                          Mitotic cyclin dependent kinase                −2.46   −2.70   
  CDK14                                         G2/M checkpoint cyclin dependent kinase                −4.56   
  FoxM1                                         Chromosome maintenance/mitotic division                −2.45   +1.88
  HELLS                                         Helicase in mitosis                                    −5.25   
  [^\^^](#tfn_002){ref-type="table-fn"}HMGA2    Transcriptional regulator in mitosis           −2.16   −4.35   
  INCENP                                        Centromere protein in mitotic progression              −2.07   
  NEK6                                          Kinase in mitotic progression                          −4.05   
  [^\#^](#tfn_003){ref-type="table-fn"}SIRT2    Deacetylase required for mitotic exit                  +2.44   

Gene name, function and fold change for each gene are listed; downregulated genes indicated by negative numbers, upregulated genes indicated by positive numbers.

Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates genes demonstrated to have PAX3-FOXO1 binding sites present in their proximal promoter \[[@R29]\]

indicates genes that demonstrate similar trends in gene expression changes in human tumor samples \[[@R30]--[@R33]\].

###### Differentially expressed mRNA important for promoting aneuploidy by altering genes important for the segregation machinery

  PROMOTION OF ANEUPLOIDY                                                                                                                          
  --------------------------------------------------------------------------------- --------------------------------------------- ------- -------- -------
  ***Segregation Machinery***                                                                                                                      
  BRCA1                                                                             Centrosomal microtubule nucleation                    −5.76    
  CEP41                                                                             Centrosomal protein                           +2.37   +16.62   
  CEP128                                                                            Centrosomal protein                                   +7.62    
  CEP170B                                                                           Microtubule organization                      −2.19            
  CKAP                                                                              Stabilizes microtubules                       −2.43            
  KIF11                                                                             Motor protein in centrosome separation                −4.67    
  KIF20A                                                                            Motor protein in centrosome separation                −3.45    
  KIF23                                                                             Kinesin -- chromosome movement in division            −3.76    +2.11
  [^\^^](#tfn_005){ref-type="table-fn"}[^\#^](#tfn_006){ref-type="table-fn"}KIF2A   Motor protein -- normal mitotic progression   −2.40   −2.41    
  [^\^^](#tfn_005){ref-type="table-fn"}KIF3A                                        Kinesin -- chromosome movement in division            +3.37    
  KNSTRN                                                                            Mitotic spindle component                             −2.39    
  NDE1                                                                              Microtubule organization and mitosis          −2.22            
  NIN                                                                               Important for centrosomal function                    −2.94    
  SDCCAG8                                                                           Centrosome associated protein                 −3.41   −4.37    
  SFI1                                                                              Mitotic spindle assembly                              −2.23    
  SPAG5                                                                             Associated with mitotic spindle                       −2.61    
  SUV39H1                                                                           Loss causes chromosome instability            −2.11   −3.05    
  TACC3                                                                             Stabilizes mitotic spindles                           −2.78    +2.16
  TOP2A                                                                             Topoisomerase -- chromatid separation         −2.67   −3.30    
  TOPBP1                                                                            Topoisomerase binding protein                 −2.01   −2.44    
  TPX2                                                                              Mitotic spindle assembly factor               −2.70   −3.43    
  [^\#^](#tfn_003){ref-type="table-fn"}TUBB                                         Major component of microtubules                       −2.25    
  TUBB2B                                                                            Major component of microtubules                       +3.26    
  [^\#^](#tfn_003){ref-type="table-fn"}TUBB4B                                       Major component of microtubules               −2.07            

Gene name, function and fold change for each gene are listed; downregulated genes indicated by negative numbers, upregulated genes indicated by positive numbers.

Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates genes demonstrated to have PAX3-FOXO1 binding sites present in their proximal promoter \[[@R29]\]

indicates genes that demonstrate similar trends in gene expression changes in human tumor samples \[[@R30]--[@R33]\].

###### Differentially expressed mRNA important for regulating proliferative control by altering genes for proliferative transcription factors and cell cycle regulatory proteins

  PROLIFERATIVE CONTROL                                                                                                                                  
  ----------------------------------------------------------------------------------- ----------------------------------------------- -------- --------- --------
  ***Transcription Factors***                                                                                                                            
  bcl6                                                                                Suppresses cellular proliferation                        +5.94     
  [^\#^](#tfn_009){ref-type="table-fn"}CREB3                                          Promotes cellular proliferation                 +2.25    +2.48     
  FOXM1                                                                               Promotes entry into S- and M-phase                       −2.45     +1.88
  [^\^^](#tfn_008){ref-type="table-fn"}[^\#^](#tfn_009){ref-type="table-fn"}FOXO1     Promotes cellular proliferation                 +3.16    +2.19     
  FOXO4                                                                               Promotes cellular proliferation                 +3.16    +3.84     
  [^\^^](#tfn_008){ref-type="table-fn"}[^\#^](#tfn_009){ref-type="table-fn"}GADD45A   Inhibits entry into S-phase                              +2.22     
  HOXB9                                                                               Promotes cellular proliferation                 +42.81   +9.25     
  KLF5                                                                                Promotes cellular proliferation                 +2.83    +2.06     
  [^\#^](#tfn_009){ref-type="table-fn"}MYC                                            Promotes cellular proliferation                          +23.59    −27.09
  NAB2                                                                                Negative cofactor -- inhibits proliferation     +2.60              
  NDN                                                                                 Prevents excessive proliferation                −2.03              
  [^\#^](#tfn_009){ref-type="table-fn"}Nupr1                                          Inhibits cellular proliferation                          +3.10     
  PML                                                                                 Promotes cellular proliferation                          −4.86     
  Suv39h1                                                                             Promotes cellular proliferation                 −2.11    −3.05     
  [^\#^](#tfn_009){ref-type="table-fn"}TFDP1                                          Promotes E2F activity/cellular proliferation             −2.06     
  UHRF1                                                                               Regulates G1/S transition                                −4.00     
  WRD6                                                                                G1 arrest -- inhibits proliferation             −2.57              
  ***Cell Cycle Regulatory Proteins***                                                                                                                   
  ARID3A                                                                              Promotes E2F transcription and growth           +4.53    +4.38     
  [^\#^](#tfn_009){ref-type="table-fn"}BTG2                                           Anti-proliferative -- inhibits Cyclin D1        −2.07              
  CCNA2                                                                               Cyclin A2 -- G1/S and G2?M progression                   −2.45     
  [^\#^](#tfn_009){ref-type="table-fn"}CCND1                                          Cyclin D1 -- G1 progression                     −5.46    −4.32     
  [^\#^](#tfn_009){ref-type="table-fn"}CCND2                                          Cyclin D2 -- G1 progression                     −5.54    −4.38     
  [^\#^](#tfn_009){ref-type="table-fn"}CCND3                                          Cyclin D3 -- G1 progression                              +4.03     
  CCNG1                                                                               Cyclin G1 -- negative regulator of cell cycle   −2.19    −2.66     
  CCPG1                                                                               Positive regulator of proliferation             +2.93              
  CCR                                                                                 Increase in G1/S -- promotes proliferation               −2.57     +2.03
  CDC20                                                                               Required for completion of mitosis              −2.27    −2.71     
  CDC25B                                                                              Required for G2/M progression                   +2.20              
  CDK1                                                                                Promotes G2/M progression                       −3.01    −2.71     
  [^\^^](#tfn_008){ref-type="table-fn"}[^\#^](#tfn_009){ref-type="table-fn"}CDK6      Promotes G1 progression                                  −2.81     
  CDK14                                                                               Promotes G1 progression                                  −4.56     
  CDK2AP                                                                              Interacts with CDK2 -- promotes proliferation   +2.48              
  cdkn1a (p21)                                                                        Inhibitor of G1 progression                              +2.19     
  cdkn1c (p57)                                                                        Inhibitor of G1 progression                     +21.71   +134.36   −5.31
  cdkn2d (p19)                                                                        Inhibitor of G1 progression                     +7.78    +2.46     
  DBF4                                                                                Required for S-phase progression                         −2.57     
  [^\^^](#tfn_008){ref-type="table-fn"}[^\#^](#tfn_009){ref-type="table-fn"}GAS1      Block entry into S-phase                                 +4.26     −3.63
  Rb1                                                                                 Tumor suppressor -- inhibits proliferation               +2.10     −2.53
  Mdm2                                                                                Facilitates G1/S phase transition               −2.11              
  NEK6                                                                                Required for M-phase progression                         −4.06     

Gene name, function and fold change for each gene are listed; downregulated genes indicated by negative numbers, upregulated genes indicated by positive numbers.

Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates genes demonstrated to have PAX3-FOXO1 binding sites present in their proximal promoter \[[@R29]\]

indicates genes that demonstrate similar trends in gene expression changes in human tumor samples \[[@R30]--[@R33]\].

###### Differentially expressed mRNA important for regulating proliferative control by altering genes for growth factors and proliferative receptors

  PROLIFERATIVE CONTROL                                                                                                                                  
  --------------------------------------------------------------------------------- -------------------------------------------------- -------- -------- --------
  ***Growth Factors/Development***                                                                                                                       
  CGREF1                                                                            Ca+2 binding inhibitor of cellular proliferation            −3.10    +2.44
  CSF1                                                                              Promotes cellular proliferation                    −5.94    −3.29    
  [^\#^](#tfn_012){ref-type="table-fn"}CYR61                                        Promotes cellular proliferation                    −3.29             
  hdgfrp3                                                                           May promote cellular proliferation                          +6.15    
  [^\#^](#tfn_012){ref-type="table-fn"}IFITM1                                       Suppresses proliferation                           −2.68             −2.89
  [^\#^](#tfn_012){ref-type="table-fn"}Igf2                                         Growth promoting hormone                                    +19.97   −3.72
  [^\#^](#tfn_012){ref-type="table-fn"}IGFBP2                                       Inhibits IGF-dependent proliferation               −8.63             
  Igfbp3                                                                            Interacts with and stabilizes IGF                           +4.35    −1.74
  [^\#^](#tfn_012){ref-type="table-fn"}Igfbp5                                       Interacts with and stabilizes IGF                  +8.28    +50.91   −5.70
  RACGAP1                                                                           Promotes cellular proliferation                             −2.68    
  [^\^^](#tfn_011){ref-type="table-fn"}SHB                                          Promotes IGF-dependent cellular proliferation      +2.93    +3.23    
  [^\#^](#tfn_012){ref-type="table-fn"}SMAD3                                        Promotes cellular proliferation                    −5.50             
  SMO                                                                               Promotes cellular proliferation                             −2.38    
  [^\#^](#tfn_012){ref-type="table-fn"}TgfB3                                        Anti-proliferative effect                                   +2.77    −2.75
  ***Receptor/Signal Transduction***                                                                                                                     
  [^\^^](#tfn_011){ref-type="table-fn"}[^\#^](#tfn_012){ref-type="table-fn"}ABI1    Negative regulator of proliferation                −2.41             
  ADRA1B                                                                            Adranergic receptor -- inhibits proliferation               −4.89    +3.34
  [^\#^](#tfn_012){ref-type="table-fn"}AKAP12                                       Suppresses proliferation                           −7.94             −3.86
  AXL                                                                               Promotes cellular proliferation                    −6.06    −4.29    
  EGFR                                                                              Epidermal growth factor receptor                            −3.32    +4.82
  EPS8                                                                              Involved in promoting EGF pathway                           −9.32    +3.58
  Erbb3                                                                             HER3 --growth factor receptor                      +3.10    +6.23    −4.06
  [^\^^](#tfn_011){ref-type="table-fn"}[^\#^](#tfn_012){ref-type="table-fn"}FGFR4   Receptor for FGF19 -- promotes proliferation       +6.11             
  GAREM                                                                             Promotes EGF-receptor proliferation                +15.78   +4.96    
  GHR                                                                               Promotes cellular growth                                    −4.66    +2.28
  [^\#^](#tfn_012){ref-type="table-fn"}Grb10                                        Negative regulator of proliferation                         +7.11    −11.47
  [^\^^](#tfn_011){ref-type="table-fn"}IGF1R                                        IGF1 growth factor receptor                                 +2.69    −2.13
  IL6ST                                                                             Promotes cellular proliferation                    +2.77    +3.05    
  [^\^^](#tfn_011){ref-type="table-fn"}IRS1                                         Involved in insulin/IGF signaling                  −2.14             
  [^\^^](#tfn_011){ref-type="table-fn"}[^\#^](#tfn_012){ref-type="table-fn"}MET     Hepatocyte growth factor receptor                           +2.91    −3.73
  NOTCH2                                                                            Promotes myoblast proliferation                             +2.38    
  SPHK2                                                                             Sphingosine kinase -- promotes proliferation       +2.16             
  Tgfbr1                                                                            Anti-proliferative effects                                  +2.25    

Gene name, function and fold change for each gene are listed; downregulated genes indicated by negative numbers, upregulated genes indicated by positive numbers.

Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates genes demonstrated to have PAX3-FOXO1 binding sites present in their proximal promoter \[[@R29]\]

indicates genes that demonstrate similar trends in gene expression changes in human tumor samples \[[@R30]--[@R33]\].

###### Differentially expressed mRNA important for regulating proliferative control by altering genes for proliferative enzymes and miscellaneous proliferative proteins

  PROLIFERATIVE CONTROL                                                                                                                              
  -------------------------------------------------------------------------------- ----------------------------------------------- -------- -------- -------
  ***Enzymatic Activity***                                                                                                                           
  [^\#^](#tfn_015){ref-type="table-fn"}ADAMTS1                                     Metalloproteinase -- promotes proliferation     +22.01   +3.63    +5.66
  BRCA1                                                                            Tumor suppressor -- inhibits proliferation               −5.78    
  [^\#^](#tfn_015){ref-type="table-fn"}DUSP1                                       Phosphatase -- inhibits proliferation           −3.61             −2.31
  DUSP4                                                                            Phosphatase -- inhibits proliferation           −3.07    −2.43    
  DUSP10                                                                           Phosphatase -- inhibits proliferation                             −2.20
  [^\^^](#tfn_014){ref-type="table-fn"}[^\#^](#tfn_015){ref-type="table-fn"}DYRK   Kinase -- inhibits cellular proliferation                +2.75    −3.34
  PDIA4                                                                            Protein disulfide isomerase -- IGFR recycler                      +2.73
  PPP6C                                                                            Phosphatase -- restricts G1/S progression                +2.57    
  [^\^^](#tfn_014){ref-type="table-fn"}PRUNE                                       Phosphodiesterase -- promotes proliferation              +3.32    −2.66
  PTPRK                                                                            Negative regulator of EGFR                               −7.89    
  TENC1                                                                            Negative regulator of Akt                                +2.45    
  [^\#^](#tfn_015){ref-type="table-fn"}TIMP2                                       Inhibits cellular proliferation                 −2.68             
  ***Other***                                                                                                                                        
  [^\#^](#tfn_015){ref-type="table-fn"}CAV1                                        Antiproliferative -- downregulates Cyclin Da             +5.31    −2.95
  CRLF3                                                                            Negative regulator of cell cycle progression             −3.10    
  EPB41L3                                                                          Suppresses proliferation                        −6.32    −3.20    
  FOSL1                                                                            Promotes cellular proliferation                 −5.21    −4.69    
  Gpnmb                                                                            Inhibits cellular proliferation                          −14.52   +3.32
  [^\#^](#tfn_015){ref-type="table-fn"}NPM1                                        Promotes cellular proliferation                          −2.31    
  PHF10                                                                            Chromatin remodeler -- promotes proliferation   +2.13    +2.99    
  SDC1                                                                             Promotes proliferation                          −2.43    −2.33    
  UBN1                                                                             Chromatin remodeler -- promotes senescence               +2.10    

Gene name, function and fold change for each gene are listed; downregulated genes indicated by negative numbers, upregulated genes indicated by positive numbers.

Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3),

indicates genes demonstrated to have PAX3-FOXO1 binding sites present in their proximal promoter \[[@R29]\]

indicates genes that demonstrate similar trends in gene expression changes in human tumor samples \[[@R30]--[@R33]\].

In our miRNA deep sequencing analysis we found a total of 104 miRNAs whose expression changed in a PAX3-FOXO1-dependent manner, 61 of which are downregulated and 43 of which are upregulated (data not shown). Using miRTarBase \[[@R34]\] we found that out of these 104 total miRNA, 19 have validated target genes important for maintaining chromosome number and integrity (10 downregulated, 9 upregulated, Table [2](#T2){ref-type="table"}), with validation on miRTarBase by at least two independent experimental methods. In addition to these 19 validated targets, we found using the TargetScan database that 22 additional miRNAs (17 downregulated, 5 upregulated, Table [2](#T2){ref-type="table"}) are highly predicted to target genes important for chromosome number and integrity, based on their predicted efficacy of targeting (context score ≥ 85%) \[[@R35], [@R36]\] or probability of conserved targeting (P~CT~) \[[@R37]\] \[P~CT~ ≥ 0.8\], as previously described \[[@R38]\], with several of the genes identified by TargetScan being validated targets in MirTarBase. Combined, the differentially expressed miRNAs target 56 additional genes that promote aneuploidy with many of these genes being targeted by multiple differentially expressed miRNA.

###### Differentially expressed miRNA that target genes important for promoting aneuploidy --- miRNA downregulated by PAX3-FOXO1 relative to empty vector

  -------------------------------------------------------------------------------------------------------------------------------------
  PROMOTION OF ANEUPLOIDY                                                                                                       
  -------------------------------------------- ------------- ---------------------------------------------- --------- --------- -------
  [\*](#tfn_016){ref-type="table-fn"}10a-5p    HDAC4         Regulates chromosome segregation               −333.33   −200.00   

  [\*](#tfn_016){ref-type="table-fn"}1a-3p     Calm1\        Regulates progression of cytokinesis\          −18.50    −11.11    
                                               Calm2\        Regulates progression of cytokinesis\                              
                                               HDAC4\        Regulates chromosome segregation\                                  
                                               Cdc42         Spindle microtubule attachment                                     

  [\*](#tfn_016){ref-type="table-fn"}376a-3p   TTK           Chromosome alignment at centromere             −11.08    −12.67    

  [\*](#tfn_016){ref-type="table-fn"}433-3p    *CEP135*      *Centrosomal protein*                          −5.52     −3.97     

  543-3p                                       *SIRT1*       *Involved in chromosome maintenance*           −4.50     −3.31     

  [\*](#tfn_016){ref-type="table-fn"}133a-3p   Cdc42\        Spindle microtubule attachment\                −3.72     −3.62     
                                               HDAC4         Regulates chromosome segregation                                   

  148b-3p                                      *CDC25B*      *Induces mitotic progression*                  −3.44     −3.70     

  [\*](#tfn_016){ref-type="table-fn"}19a-3p    *CEP350*\     *Anchors microtubules to centrosome*\          −2.87     −2.84     
                                               *MAPRE2*      *Anchors microtubules to centrosome*                               

  [\*](#tfn_016){ref-type="table-fn"}351-5p    *NINL*\       *Mitotic spindle assembly*\                    −2.43     −2.12     
                                               *SUV39H1*     *Methylase important for segregation*                              

  3099-3p                                      *KIF3B*       *Tethers chromosomes to spindle pole*          −2.36     −4.20     

  133b-5p                                      *Myh9*        *Important for cytokinesis*                    −2.26     −2.89     

  504-5p                                       *CEP170*      *Centrosomal protein*                          −2.09     −3.87     

  [\*](#tfn_016){ref-type="table-fn"}335-5p    *CHFR*\       *Regulates entry into mitosis*\                −12.50    −37.04    +2.95
                                               *d4*          *Regulates chromosome stability*                                   

  486-3p                                       PTEN          Chromosome stability                           −6.70     −13.20    +1.97

  [\*](#tfn_016){ref-type="table-fn"}128-3p    *NEK6*\       *Required for chromosome segregation*\         −2.17     −4.85     +2.32
                                               *PARD6B*\     *Involved in asymmetrical cell division*\                          
                                               *PDS5B*       *Important for sister chromatid cohesion*                          

  [\*](#tfn_016){ref-type="table-fn"}339-5p    *MAPRE1*      *Anchors microtubules at centrosome*           −1.93     −4.24     +2.19

  [\*](#tfn_016){ref-type="table-fn"}148a-3p   CamK2\        Spindle depolarization\                        −4.41               −2.98
                                               *CDC25B*\     *Induces mitotic progression*\                                     
                                               *CCNF*\       *Inhibitor of centrosome reduplication*\                           
                                               *PTEN*\       *Chromosome stability*\                                            
                                               *RCC2*        *Regulates chromosome condensation*                                

  [\*](#tfn_016){ref-type="table-fn"}29a-3p    HDAC4\        Regulates chromosome segregation\              −2.65               
                                               MCL1\         Inhibits BCL2 and apoptosis\                                       
                                               *Tubb2B*\     *Component of microtubules*\                                       
                                               *KIF3B*\      *Tethers chromosomes to spindle pole*\                             
                                               *CEP68*\      *Centrosomal protein*\                                             
                                               *PTEN*\       *Chromosome stability*\                                            
                                               *CDC42BPA*\   *Regulates CDC42*\                                                 
                                               *MAPRE2*      *Anchors microtubules to centrosome*                               

  3968                                         *ESCO2*       *Establishment of sister chromatid cohesion*   −2.53               

  [\*](#tfn_016){ref-type="table-fn"}322-5p    Arl2\         Regulates centrosome integrity\                −2.42               
                                               *CDC27*       *Regulates mitotic progression*                                    

  [\*](#tfn_016){ref-type="table-fn"}9-5p      SIRT1\        Involved in chromosome maintenance\                      −5.75     +9.73
                                               *CCNG1*\      *Associated with G2/M arrest*\                                     
                                               *CDC14B*\     *Controls exit of mitosis*\                                        
                                               *CEP350*      *Centrosomal protein*                                              

  133b-3p                                      Pitx3         Important for mitotic activity                           −4.83     +5.74

  [\*](#tfn_016){ref-type="table-fn"}486-5p    PTEN          Chromosome stability                                     −2.80     +2.09

  [\*](#tfn_016){ref-type="table-fn"}206-5p    *HDAC4*       *Regulates chromosome stability*                         −2.63     +2.31
  -------------------------------------------------------------------------------------------------------------------------------------

The microRNA, target gene name, function, and fold change for each miRNA are listed; downregulated microRNA indicated by negative numbers, upregulated miRNA indicated by positive numbers. Genes and functions listed in normal font indicate validated targets; genes and functions listed in italics indicate genes highly predicted to be targets of the indicated microRNA. Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates miRNA that target genes involved with the promotion of aneuploidy and in proliferative control.

###### Differentially expressed miRNA that target genes important for promoting aneuploidy --- miRNA upregulated by PAX3-FOXO1 relative to empty vector

  --------------------------------------------------------------------------------------------------------------------------------
  PROMOTION OF ANEUPLOIDY                                                                                                  
  ---------------------------------------------- --------- --------------------------------------------- -------- -------- -------
  615-3p                                         MAPT      Determines polarity of the centrosome         +30.45   +6.08    +5.01

  [\*](#tfn_016){ref-type="table-fn"}31-3p       RHOA      Signaling protein important for cytokinesis   +4.19    +2.04    +2.05

  [\*](#tfn_016){ref-type="table-fn"}196a-5p     Hmga2\    Chromosome condensation -- G2/M phase\        +24.39   +19.33   
                                                 RCC2      Regulator of chromosome condensation                            

  92a-1-5p                                       TACC2     Organizes centrosomal microtubules            +3.35    +3.55    

  [\*](#tfn_016){ref-type="table-fn"}301a-3p     MDM4\     Regulates chromosome stability\               +3.07    +2.33    
                                                 CENPO     Necessary for chromosome segregation                            

  [\*](#tfn_016){ref-type="table-fn"}16-5p       Arl2\     Regulates centrosome integrity\               +2.07    +2.56    
                                                 MDM4\     Regulates chromosome stability\                                 
                                                 G2E3      Important for mitotic progression                               

  [\*](#tfn_016){ref-type="table-fn"}222-3p      PTEN      Chromosome stability                          +2.78    +7.02    −2.52

  [\*](#tfn_016){ref-type="table-fn"}221-3p      PTEN      Chromosome stability                          +2.10    +7.02    −2.52

  [\*](#tfn_016){ref-type="table-fn"}30c-2-5p    RCC2\     Regulator of chromosome condensation\                  +3.55    −2.32
                                                 CEP350    Anchors microtubules at centrosome                              

  20a-5p                                         Mapk4\    Important for cytokinesis\                             +2.01    
                                                 PTEN      Chromosome stability                                            

  [\*](#tfn_016){ref-type="table-fn"}130b-3p     MAP4      Important for chromosome segregation          +3.39             +2.20

  421-3p                                         ARHGEF9   Regulates spindle microtubule attachment      +3.22             +3.27

  [\*](#tfn_016){ref-type="table-fn"}206-3p      Hdac4\    Regulates chromosome segregation\             +2.42             +4.49
                                                 Tppp\     Mitotic spindle assembly\                                       
                                                 CORO1C    Potential role in cytokinesis                                   

  [\*](#tfn_016){ref-type="table-fn"}15b-5p      Arl2\     Regulates centrosome integrity\               +2.86             
                                                 CDC25A    Induces mitotic progression                                     

  183-5p                                         KIF2A     Microtubule associated protein -- mitosis     +2.05             

  [\*](#tfn_016){ref-type="table-fn"}Let-7g-5p   HMGA2     Transcriptional regulator in mitosis                   +2.04    −2.15
  --------------------------------------------------------------------------------------------------------------------------------

The microRNA, target gene name, function, and fold change for each miRNA are listed; downregulated microRNA indicated by negative numbers, upregulated miRNA indicated by positive numbers. Genes and functions listed in normal font indicate validated targets; genes and functions listed in italics indicate genes highly predicted to be targets of the indicated microRNA. Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates miRNA that target genes involved with the promotion of aneuploidy and in proliferative control.

###### Differentially expressed miRNA that target genes important for proliferative control --- miRNA downregulated by PAX3-FOXO1 relative to empty vector

  --------------------------------------------------------------------------------------------------------------------------------
  PROLIFERATIVE CONTROL                                                                                                    
  -------------------------------------------- --------- --------------------------------------------- --------- --------- -------
  [\*](#tfn_018){ref-type="table-fn"}10a-5p    HDAC4     Histone deacetylase 4 -- pro-proliferative    −333.33   −200.00   

  143-3p                                       Kras\     G-protein coupled receptor\                   −22.22    −17.85    
                                               Ptn       Secreted growth factor -- mitogenic                               

  [\*](#tfn_018){ref-type="table-fn"}1a-3p     HDAC4\    Pro-proliferative\                            −18.50    −11.11    
                                               IGF1\     Insulin like growth factor - proliferative\                       
                                               Igf1R\    Insulin like growth factor receptor\                              
                                               PDGFA\    Growth factor -- promotes proliferation\                          
                                               TIMP3     Inhibits cellular proliferation                                   

  133a-5p                                      INSR\     Insulin receptor -- proliferative\            −16.76    −12.67    
                                               FGF1\     Growth factor ligand -- proliferative\                            
                                               FGFR1     Growth factor ligand -- proliferative                             

  [\*](#tfn_018){ref-type="table-fn"}376a-3p   CDK2\     Cyclin dependent kinase -- G1/S\              −11.08    −13.56    
                                               IGF1R     Insulin like growth factor 1 receptor                             

  [\*](#tfn_018){ref-type="table-fn"}433-3p    GRB2      EGF-dependent proliferation                   −5.52     −3.97     

  [\*](#tfn_018){ref-type="table-fn"}133a-3p   Spry1\    Antagonist of the FGF pathway\                −3.72     −3.62     
                                               CCND2\    Cyclin D2 -- cell cycle regulation\                               
                                               Igf1R\    Insulin like growth factor 1 receptor\                            
                                               EGFR      Epidermal growth factor receptor                                  

  362-3p                                       CDKN1A\   Cyclin dependent kinase inhibitor (p57)\      −3.67     −3.21     
                                               Rb1\      Cell cycle regulatory protein\                                    
                                               HBEGF     Growth factor with EGFR and ERRB2                                 

  [\*](#tfn_018){ref-type="table-fn"}19a-3p    CDKN1A\   Cyclin dependent kinase inhibitor (p57)\      −2.87     −2.84     
                                               CCND1\    Cyclin D1 -- G1/S progression\                                    
                                               MDM4\     Promotes cellular proliferation\                                  
                                               MAPK1\    Kinase -- promotes proliferation\                                 
                                               HDAC4\    Histone deacetylase 4 -- proliferative\                           
                                               GRB10\    Negative regulator of proliferation\                              
                                               IGFBP3\   Interacts with and stabilizes IGF\                                
                                               CCND2     Cyclin D2 -- promotes cell cycle                                  

  [\*](#tfn_018){ref-type="table-fn"}34b-5p    E2F3      Promotes cell cycle progression               −2.60     −2.43     

  [\*](#tfn_018){ref-type="table-fn"}351-5p    E2F2      Promotes cell cycle progression               −2.43     −2.12     

  [\*](#tfn_018){ref-type="table-fn"}335-5p    Rb1       Tumor suppressor -- cell cycle regulator      −12.50    −37.04    +2.95

  145a-5p                                      Hoxa9\    Homeobox transcription factor\                −7.59     −14.83    +1.95
                                               IRS1\     Insulin signaling pathway\                                        
                                               Kras\     Protooncogene -- proliferative\                                   
                                               CCND2     Cylcin D2 -- cell cycle regulation                                

  335-3p                                       IGF1R     IGF1 receptor -- pro-proliferative            −5.85     −15.87    +2.72

  [\*](#tfn_018){ref-type="table-fn"}128-3p    Trim71\   E3-ubiquitin ligase --G1/S transition\        −2.17     −4.85     +2.32
                                               FoxP1\    Inhibits proliferation\                                           
                                               c-Met\    Hepatocyte growth factor receptor\                                
                                               IRS1\     Involved with insulin signaling\                                  
                                               SOS1      Promotes cellular proliferation                                   

  [\*](#tfn_018){ref-type="table-fn"}339-5p    Kdm6b     Histone demethylase -- pro-proliferative      −1.93     −4.24     +2.19

  [\*](#tfn_018){ref-type="table-fn"}148a-3p   Kdm6b\    Histone demethylase -- pro-proliferative\     −4.41               −2.98
                                               Dnmt1\    DNA methyltransferase -- pro-proliferative\                       
                                               ERBB3\    Human epidermal growth factor receptor\                           
                                               CDC25B\   Required for G2/M progression\                                    
                                               CDKN1B\   Inhibitor of G1 progression\                                      
                                               E2F7      Promotes cell cycle progression                                   

  [\*](#tfn_018){ref-type="table-fn"}181c-5p   KRAS\     Promotes cell cycle progression\              −2.34               −3.95
                                               E2F7      Proto-oncogene -- proliferative                                   

  149-3p                                       E2F1\     Cell cycle regulatory transcription factor\   −2.34     +2.99     −7.04
                                               MYBL2     Proliferative transcription factor                                

  [\*](#tfn_018){ref-type="table-fn"}29a-3p    CDK6\     Promotes G1 progression\                      −2.65               
                                               PDGFRB\   Promotes proliferation\                                           
                                               PDGFA\    Promotes proliferation\                                           
                                               FOXO3\    Promotes proliferation\                                           
                                               PDGFB     Promotes proliferation                                            

  [\*](#tfn_018){ref-type="table-fn"}322-5p    CDC27     Promotes M-phase progression                  −2.42               

  340-5p                                       MET       Hepatocyte growth factor receptor             −2.06               

  450a-5p                                      DUSP10    Negative regulator of proliferation                     −2.03     

  [\*](#tfn_018){ref-type="table-fn"}9-5p      CDKN1A\   Cyclin dependent kinase inhibitor (p21)\                −5.75     +9.73
                                               Hes1\     Promotes proliferation\                                           
                                               FGF5\     Growth factor -- promotes proliferation\                          
                                               BRAF\     Pro-proliferative kinase\                                         
                                               CDC25A\   Cell Cycle regulatory protein\                                    
                                               IGFBP3\   Interacts with and stabilizes IGF\                                
                                               FOXO1\    Promotes cellular proliferation\                                  
                                               FOXO3\    Promotes cellular proliferation\                                  
                                               HDAC5     Promotes cellular proliferation                                   

  [\*](#tfn_018){ref-type="table-fn"}486-5p    FOXO1     Promotes cellular proliferation                         −2.80     +2.09

  [\*](#tfn_018){ref-type="table-fn"}206-5p    HDAC4     Histone deacetylase 4 -- pro-proliferative              −2.63     +2.31

  345-5p                                       CDKN1A\   Cyclin dependent kinase inhibitor (p21)\                −2.39     +3.09
                                               IGFBP5    Interacts with and stabilizes IGF                                 

  23b-3p                                       Hes1\     Promotes proliferation\                                 −2.10     +2.19
                                               MET       Hepatocyte growth factor receptor                                 
  --------------------------------------------------------------------------------------------------------------------------------

The microRNA, target gene name, function, and fold change for each miRNA are listed; downregulated microRNA indicated by negative numbers, upregulated miRNA indicated by positive numbers. Genes and functions listed in normal font indicate validated targets; genes and functions listed in italics indicate genes highly predicted to be targets of the indicated microRNA. Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates miRNA that target genes involved with the promotion of aneuploidy and in proliferative control.

###### Differentially expressed miRNA that target genes important for proliferative control --- miRNA upregulated by PAX3-FOXO1 relative to empty vector

  --------------------------------------------------------------------------------------------------------------------------------
  PROLIFERATIVE CONTROL                                                                                                    
  ---------------------------------------------- ---------- -------------------------------------------- -------- -------- -------
  [\*](#tfn_019){ref-type="table-fn"}31-3p       ERBB2\     HER2 growth factor receptor\                 +4.19    +2.04    +2.05
                                                 E2F1       Cell cycle regulatory transcription factor                     

  [\*](#tfn_019){ref-type="table-fn"}196a-5p     CDKN1B\    Cyclin dependent kinase inhibitor\           +24.39   +19.33   
                                                 HMGA2\     Promotes myoblast proliferation\                               
                                                 ING5       Inhibitor of growth -- p53 pathway                             

  [\*](#tfn_019){ref-type="table-fn"}301a-3p     E2F2\      Promotes cell cycle progression\             +3.07    +2.33    
                                                 E2F7\      Promotes cell cycle progression\                               
                                                 ERBB4\     HER4 -- growth factor receptor\                                
                                                 JARID2\    Inhibits proliferation\                                        
                                                 MAPK1\     Promotes proliferation\                                        
                                                 MDM4\      Promotes proliferation\                                        
                                                 PTEN       Inhibits proliferation                                         

  [\*](#tfn_019){ref-type="table-fn"}16-5p       Wnt3a\     Promotes proliferation\                      +2.07    +2.56    
                                                 CCND1\     Cylcin D1 -- G1 progression\                                   
                                                 Mdm4\      Promotes proliferation\                                        
                                                 Jun\       Transcription factor\                                          
                                                 CCNE1\     Cyclin E1 -- G1/S transition\                                  
                                                 G2E3\      G2/M-specific E3 Ubiquitin ligase\                             
                                                 FGF7\      Growth factor -- pro-proliferative\                            
                                                 FGF2       Growth factor -- pro-proliferative                             

  [\*](#tfn_019){ref-type="table-fn"}222-3p      CDKN1B     Cyclin-dependent kinase inhibitor            +2.78    +7.02    −2.52

  [\*](#tfn_019){ref-type="table-fn"}155-5p      Jarid2\    Inhibits proliferation\                      +2.18    +5.54    −2.53
                                                 Myb\       Regulates proliferation\                                       
                                                 FGF7\      Fibroblast growth factor ligand\                               
                                                 Fos        Transcription factor                                           

  [\*](#tfn_019){ref-type="table-fn"}221-3p      CDKN1B     Cyclin dependent kinase inhibitor (p57       +2.10    +6.97    −3.31

  92b-5p                                         CDKN1C     Cyclin dependent kinase inhibitor (p16)               +3.75    −2.77

  [\*](#tfn_019){ref-type="table-fn"}30c-2-5p    HDAC4\     Promotes proliferation\                               +3.55    −2.32
                                                 MAPKBP1\   Promotes proliferation\                                        
                                                 ATF1\      Promotes proliferation\                                        
                                                 KRAS\      Proto-oncogene -- proliferative\                               
                                                 IRS2\      Insulin signaling pathway\                                     
                                                 IGF1R\     Insulin receptor -- proliferative\                             
                                                 FOXO3      Promotes proliferation                                         

  181c-3p                                        E2F7       Promotes cell cycle                                   +2.74    −3.77

  [\*](#tfn_019){ref-type="table-fn"}30a-5p      Egfr\      Growth factor receptor -- proliferative\              +2.44    −2.50
                                                 RUNX2\     Inhibits cellular proliferation\                               
                                                 SOS\       Promotes cellular proliferation\                               
                                                 IGF1R      Growth factor receptor                                         

  99a-5p                                         FGFR3\     Growth factor receptor\                               +2.05    −2.45
                                                 IGF1R\     Growth factor receptor\                                        
                                                 FOXO4      Proliferative transcription factor                             

  [\*](#tfn_019){ref-type="table-fn"}Let-7g-5p   Myc\       Proliferative transcription factor\                   +2.04    −2.15
                                                 IGFBP1\    Inhibits IGF-dependent proliferation\                          
                                                 CDKN2A     Cyclin dependent kinase inhibitor (p16)                        

  [\*](#tfn_019){ref-type="table-fn"}130b-3p     MET\       Hepatocyte growth factor receptor\           +3.39             +2.20
                                                 MAPK1\     Kinase -- promotes proliferation\                              
                                                 JARID2\    Inhibits proliferation\                                        
                                                 E2F2\      Promotes cell cycle progression\                               
                                                 E2F7\      Promotes cell cycle progression\                               
                                                 ERBB4\     HER4 -- growth factor receptor\                                
                                                 PTEN\      Inhibits proliferation\                                        
                                                 MDM4       Promotes proliferation                                         

  [\*](#tfn_019){ref-type="table-fn"}206-3p      HDAC4\     Promotes proliferation\                      +2.42             +4.49
                                                 Spry1\     Antagonist of the FGF pathway\                                 
                                                 Id1\       Promotes proliferation\                                        
                                                 TIMP3      Inhibits proliferation                                         

  [\*](#tfn_019){ref-type="table-fn"}15b-5p      CCNE2\     Cyclin E -- G1/S phase progression\          +2.86             
                                                 CCND1\     Cyclin D -- G1/S phase progression\                            
                                                 MYB        Promotes proliferation                                         

  [\*](#tfn_019){ref-type="table-fn"}30b-5p      CCNE2      Cyclin E -- G1/S phase progression           +1.98             
  --------------------------------------------------------------------------------------------------------------------------------

The microRNA, target gene name, function, and fold change for each miRNA are listed; downregulated microRNA indicated by negative numbers, upregulated miRNA indicated by positive numbers. Genes and functions listed in normal font indicate validated targets; genes and functions listed in italics indicate genes highly predicted to be targets of the indicated microRNA. Comparisons are made between empty vector and PAX3-FOXO1 (V vs. PF), PAX3 and PAX3-FOXO1 (P3 vs. PF) or empty vector and PAX3 (V vs. P3)

indicates miRNA that target genes involved with the promotion of aneuploidy and in proliferative control.

To determine if the PAX3-FOXO1-dependent mRNA and miRNA changes translate into differences in chromosome number and structure, we performed a cytogenetic analysis of proliferating primary myoblasts (Table [3A](#T3a){ref-type="table"} and Figure [1C](#F1){ref-type="fig"}) and found that the majority (48/62 cells - 77.4%) of cells transduced with empty vector contain the normal complement of 40 (2N) or 80 (4N) chromosomes, which is consistent with previous reports for the presence of diploidy and tetraploidy in proliferating myoblasts \[[@R39]\]. In a similar manner, a majority of cells (46/50 cells - 92%) ectopically expressing PAX3 contained the normal complement of chromosomes, demonstrating that the process of transduction and ectopic expression of protein does not affect chromosome number or structure. In contrast, nearly all of the cells stably expressing PAX3-FOXO1 (93/103 cells - 90.3%) had hypodiploid (\<2N) or hyperdiploid/hypotetraploid (\>2N to \<4N) chromosome numbers. The numbers of chromosomes seen in individual cells, along with the variation of chromosome numbers between cells correlates will with results seen in ARMS primary tumor samples \[[@R11], [@R15]--[@R18]\].

###### Quantification of PAX3-FOXO1-dependent aneuploidy on cells stably transduced with empty vector (Vector), PAX3, PAX3-FOXO1, or the PAX3-FOXO1 phosphomutants (S201A, S205A, and S209A)

  Sample                               Chromosome Number                                                       
  ------------ ----------------------- ------------------- ------------ ------------------------- ------------ -------------
               Number cells analyzed   \<2N (\<40)         2N (40)      \>2N to \<4N (41 -- 79)   4N (80)      \>4N (\>80)
  Vector       62                      7 (11.3%)           25 (40.3%)   7 (11.3%)                 23 (37.1%)   0 (0.0%)
  PAX3         50                      2 (4.0%)            34 (68.0%)   2 (4.0%)                  12 (24.0%)   0 (0.0%)
  PAX3-FOXO1   103                     51 (49.5%)          6 (5.8%)     42 (40.8%)                4 (3.9 %)    0 (0.0%)
  S201A        64                      29 (45.3%)          5 (7.8%)     27 (42.2%)                2 (3.1%)     1 (1.5%)
  S205A        69                      13 (18.8%)          3 (4.3%)     45 (65.2%)                4 (5.8%)     4 (5.8%)
  S209A        57                      18 (31.6%)          2 (3.5%)     29 (50.8%)                0 (0.0%)     8 (14.0%)

The chromosome number for individual cells was determined and classified as hypodiploid (\<2N), diploid (2N), hyperdiploid/hypotetrapoid (\>2N to \<4N), tetraploid (4N) or hypertetraploid (\>4N)

###### Quantification of PAX3-FOXO1-dependent chromosomal structural abnormalities

  Sample       Number cells analyzed   Sister Chromatid Dissociation   Telomere Association   Double Minutes                        
  ------------ ----------------------- ------------------------------- ---------------------- ---------------- --------- ---------- ---------
  Vector       62                      1 (1.6%)                        2                      2 (3.2%)         2         0 (0.0%)   0
  PAX3         50                      2 (4.0%)                        2                      2 (4.0%)         2         0 (0.0%)   0
  PAX3-FOXO1   103                     16 (15.5%)                      1 -- 5                 17 (16.5%)       1 -- 16   4 (3.9%)   5 -- 20
  S201A        64                      6 (9.4%)                        2 -- 6                 21 (32.8%)       2 -- 18   4 (6.3%)   6 -- 12
  S205A        69                      9 (13.0%)                       1 -- 3                 20 (28.9%)       1 -- 4    5 (7.2%)   1 -- 62
  S209A        57                      7 (12.3%)                       5 -- 63                6 (10.5%)        1 -- 3    4 (7.0%)   5 -- 40

Metaphase chromosome analysis on cells stably transduced with empty vector (Vector), PAX3, PAX3-FOXO1, or the PAX3-FOXO1 phosphomutants (S201A, S205A, or S209A). The number of cells containing the indicated structural abnormality along with a range of the number of occurrences of the abnormality within each cell is listed.

Further, we observed an increased number of disrupted chromosomal structures in cells stably expressing PAX3-FOXO1 relative to the negative control cells (vector and PAX3). We noted 16 cells (15.5%) with sister chromatid dissociation (Figure [1C](#F1){ref-type="fig"}, right panel, solid arrows), 17 cells (16.5%) with telomere association, and 4 cells (3.9%) with double minutes (Table [1B](#T1b){ref-type="table"}) with only two of these cells having the presence of both sister chromatid dissociation and telomere association. Although some chromosomal disruptions were observed in the control cells, these events were minimal (incidence \<4%) and did not include the presence of double minutes (Table [3B](#T3b){ref-type="table"}).

We previously published that PAX3-FOXO1 is phosphorylated at three independent sites \[[@R27], [@R28], [@R40]\] and phosphorylation contributes to ARMS oncogenic phenotypes in an *in vitro* cellular model \[[@R26]\]. To determine how phosphorylation at these sites affects PAX3-FOXO1-dependent changes in chromosome number and structure, we utilized mutants in which each individual site was mutated to a phospho-incompetent alanine (S201A, S205A, or S209A) \[[@R26]\]. A Western blot analysis of mouse primary myoblasts stably transduced with these mutants demonstrates that all mutants were expressed to levels equivalent to that of wild-type PAX3-FOXO1 (Figure [1B](#F1){ref-type="fig"}).

Cytogenetic analysis demonstrated that similar to wild-type PAX3-FOXO1, a majority of cells stably expressing S201A \[57/64 cells - 89.1%\], S205A \[62/69 cells - 89.8%\], and S209A \[55/57 cells - 96.5%\] had chromosome numbers \<2N or \>2N to \<4N with an increase in the number of hypertetraploid cells (\>4N) for all three samples (Table [3A](#T3a){ref-type="table"}). We also observed similar chromosomal abnormalities for each of the phopsho-incompetent mutants relative to wild-type PAX3-FOXO1 (Figure [1D](#F1){ref-type="fig"}); however, the individual phosphorylation events seem to impact these chromosomal aberrations differently (Table [3B](#T3b){ref-type="table"}). While all three mutants have a similar percentage of cells containing sister chromatid dissociation relative to wild-type PAX3-FOXO1, the expression of S209A increased the number of individual events within each cell, with some cells having over 60 dissociations. Although both S201A and S205A increased the percentage of cells with telomere association, loss of phosphorylation at S205 or S209 decreased the number of individual events within each cell relative to PAX3-FOXO1. Finally, double minutes were present in a similar percentage of cells expressing the fusion protein as either wild type or mutant. However, cells stably expressing the S205A mutant had an increased number of double minutes per cell relative to the wild-type fusion protein. Taken together, these results are the first to demonstrate that the presence of an oncogenic fusion protein, PAX3-FOXO1, is sufficient to promote aneuploidy and disrupt chromosome structure and that phosphorylation contributes to this state.

PAX3-FOXO1 overrides cell cycle inhibition to enhance cellular proliferation {#s2_2}
----------------------------------------------------------------------------

One of the initial cellular responses to aneuploidy is an attenuation of proliferation \[[@R41]\]. An examination of our comparative transcriptomic analysis revealed that of the 846 differentially expressed mRNA, 93 (nearly 11%) have biological functions important for cellular proliferation (Table [1](#T1){ref-type="table"}), twelve of which have previously described PAX3-FOXO1 binding sites in their proximal promoter (Table [1](#T1){ref-type="table"}, carat) \[[@R29]\], and 30 had altered gene expression levels consistent with changes seen in human tumor samples \[[@R30]--[@R33]\] (Table [1](#T1){ref-type="table"}, pound sign). We also found 13 of the downregulated and 9 of the upregulated miRNAs are experimentally validated on miRTarBase to target mRNA whose biological function is important for proliferative control. Further, 15 of the downregulated and 9 of the upregulated miRNAs are highly predicted to target growth regulatory genes (Table [2](#T2){ref-type="table"}), based on their predicted efficacy of targeting or probability of conserved targeting, as described above.

Consistent with the predicted cellular response to the aneuploid state, we found that of the 93 alternatively expressed mRNA, 23 are cell cycle regulatory genes and include decreases in cyclins and their related cyclin dependent kinases and increases in the expression of cyclin dependent kinase inhibitors (Table [1](#T1){ref-type="table"}). Further, we found 11 of the downregulated and 12 of the upregulated miRNAs also affect cell cycle regulatory proteins in a manner consistent with the attenuation of growth. To determine how these changes translate into effects on cellular growth, we determined doubling times of primary myoblasts stably transduced with empty vector, PAX3, or PAX3-FOXO1. We found the doubling time of primary myoblasts transduced with empty vector to be approximately 35 hours and that the stable expression of PAX3 enhanced the growth rate by reducing the doubling time to approximately 20 hours (Figure [2](#F2){ref-type="fig"}). Primary myoblasts stably expressing PAX3-FOXO1 also had a reduced doubling time of approximately 20 hours (Figure [2](#F2){ref-type="fig"}), a result that seems to be in contrast to the presence of aneuploidy in these cells and the observed changes in cell cycle regulatory mRNA and miRNA. Further, we determined proliferation rates on primary myoblasts stably expressing the PAX3-FOXO1 phospho-mutants. We found that although cells expressing S201A have an enhanced proliferation rate relative to the negative control, the rate is significantly slower than for cells stably expressing wild-type PAX3-FOXO1 (Figure [2](#F2){ref-type="fig"}). The stable expression of S205A and S209A resulted in proliferation rates that were indistinguishable from the empty vector negative control.

![Stably transduced primary myoblasts (vector, PAX3, wild-type PAX3-FOXO1, or PAX3-FOXO1 phosphomutant) were plated, grown for four days, growth determined using the CCK-8 cell counting kit and plotted as a function of time (A) from which doubling times were determined, as described in the Materials and Methods\
Error bars represent the standard deviation from three independent determinations and *P*-values were computed using non-parametric two-way ANOVA analyses comparing each treatment condition to the empty vector negative control. (\*\**P* = 0.005, \*\*\*\**P* \< 0.0001).](oncotarget-07-62814-g002){#F2}

To better understand this result, we examined our mRNA and miRNA comparative transcriptomic analyses for alterations in mRNA and miRNAs whose biological functions may affect growth independent of cell cycle regulatory proteins. We found that the expression of PAX3-FOXO1 is sufficient to alter the mRNA for multiple growth factors (14 genes) and growth factor receptors (18 genes) in a manner that is in direct alignment with our observed increased proliferation rate. These include the growth factor receptors c-MET \[[@R22]\], and IGF1R \[[@R20]\] (both direct targets of PAX3-FOXO1), FGFR4, Erbb3 (HER3), IL6ST, and the receptor NOTCH2, which in certain cell types enhances proliferation. We also found the increased expression of many of the associated growth factors including IGF2, IGFBP3, and IGFBP5 and several proliferative transcription factors (17 genes), including CREB3, FOXO4, HOXB9, and Myc (Table [1](#T1){ref-type="table"}). Further, most of the miRNA have validated or predicted targets that are growth factor receptors, growth factors, or proliferative transcription factors (Table [2](#T2){ref-type="table"}). Interestingly, 18 of the downregulated and 13 of the upregulated miRNAs target genes important for both aneuploidy and the regulation of proliferative control. Taken together, these results demonstrate that the expression of an oncogene is sufficient to override aneuploid-dependent attenuation of growth by globally altering the expression of growth factor related mRNA and miRNA.

Phosphorylation contributes to PAX3-FOXO1-dependent differential gene expression {#s2_3}
--------------------------------------------------------------------------------

To determine how phosphorylation of PAX3-FOXO1 affects the expression of genes important for maintaining chromosome number and structure, we performed a qRT-PCR analysis on a subset of genes with fusion protein-dependent altered expression. We tested genes in chromosome segregation (AurkA), chromosome cohesion (BUB1, Cep250, and Sgol1), and cytokinesis (COROC1, Myh10, and Prc1). We observed changes in gene expression consistent with our mRNA deep sequencing results, in which the presence of PAX3-FOXO1 promotes a significant decrease in the expression of all seven genes (Figure [3A](#F3){ref-type="fig"}). Further, with the exception of Myh10 and Cep250, we found inhibiting the phosphorylation of PAX3-FOXO1 at Ser201 or Ser205 corrected these decreases, with gene expression levels equivalent to the empty vector or PAX3 controls (Figure [3A](#F3){ref-type="fig"}). However, loss of phosphorylation at Ser209 was unable to correct these decreases and in fact promoted a further 2-fold decrease in the expression of Prc1.

![Quantitative RT-PCR analysis for aneuploidy mRNA (A), proliferation mRNA (B) and miRNA (C)\
Total RNA was isolated from stably transduced cells \[empty vector (white), PAX3 (stippled), PAX3-FOXO1 (black), or the phosphomutants S201A (light gray), S205A (medium gray), or S209A (hashed gray). Quantitative RT-PCR was performed using primers specific for the indicated mRNA **A.** and **B.** or microRNA **C.**, as described in the Materials and Methods. Error bars represent the standard deviation from three independent determinations and P-values were computed using non-parametric two-way ANOVA analyses. The asterisk indicates statistical comparisons between empty vector and each sample (\**P* = 0.001, \*\**P* \< 0.0001). The hash-tap indicates comparisons between wild-type PAX3-FOXO1 and the sample (\#*P* = 0.001).](oncotarget-07-62814-g003){#F3}

A qRT-PCR analysis on a subset of proliferation genes, including cell cycle regulatory genes (CDKN1C, CDK1, and Cyclin D1) and growth factor genes (Erbb3, IGF2, and IGFBP5) once again showed PAX3-FOXO1-dependent changes consistent with our mRNA deep sequencing results (Figure [3B](#F3){ref-type="fig"}). We found the stable expression of the phospho-incompetent mutants also increased (CDKN1C) or decreased (CDK1 and Cyclin D1) cell cycle regulatory gene expression relative to the negative control. However, with the exception of CDK1 in cells expressing the S209A mutant, these changes were much less severe relative to wild-type PAX3-FOXO1. With respect to growth factor related genes, we found that the S209A mutant reduced the expression of all three genes to levels indistinguishable from the negative control. Further, the expression of S201A and S205A also altered the expression of IGF2 and IGFBP5 that trended toward background levels, but had little effect on the expression of Erbb3.

We performed a similar quantitative analysis on a select set of miRNAs, chosen for their ability to target genes important for the promotion of aneuploidy and for the regulation of proliferation. We found changes in miRNA expression consistent with our deep sequencing results (Figure [3C](#F3){ref-type="fig"}). As with our mRNA results, we found that inhibiting phosphorylation of PAX3-FOXO1 at Ser201 or Ser205 returned miRNA expression levels to that of the empty vector or PAX3 controls (Figure [3C](#F3){ref-type="fig"}). While loss of phosphorylation at Ser209 was able to correct the altered miRNA expression for miR30c-2-5p, S209A had no effect on the altered expression of miR130b-3p. Interestingly, the expression of S209A resulted in a 2- or 4-fold increase in the expression of miR-196a-5p and miR301a-3p, respectively, relative to wild-type PAX3-FOXO1 (Figure [3C](#F3){ref-type="fig"}). Taken together, our results demonstrate that phosphorylation contributes to the altered expression of genes and miRNAs important for the PAX3-FOXO1-dependent promotion of aneuploidy, aberrant chromosome structure, and regulation of growth.

DISCUSSION {#s3}
==========

Aneuploidy is common in solid tumors, which given the enhanced proliferative activity of transformed or malignant cells, suggests that these cells have acquired mechanisms to overcome proliferative defects associated with this state. In this report we demonstrate for the first time that the presence of an oncogenic protein, PAX3-FOXO1, is sufficient to serve as a driving mutation to initiate a cascade of changes in mRNA and miRNA whose biological functions are important for maintaining proper chromosome number and structure and proliferative control (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). We show that these changes translate into biological effects, since cells expressing PAX3-FOXO1 are primarily aneuploid (Table [3A](#T3a){ref-type="table"}), have altered chromosome structure (Table [3B](#T3b){ref-type="table"}), and have compensated to override the anti-proliferative responses to aneuploidy in physiologically relevant primary myoblasts (Figure [2](#F2){ref-type="fig"}). Consistent with our previous work \[[@R26]\], we demonstrate that inhibiting PAX3-FOXO1 phosphorylation reverts many of the gene expression changes to background levels (Figure [3](#F3){ref-type="fig"}), which translate into biological effects by altering the extent of chromosome structural abnormalities (Figure [1](#F1){ref-type="fig"} and Table [3B](#T3b){ref-type="table"}) and enhanced proliferation rates (Figure [2](#F2){ref-type="fig"}). Given that these changes result explicitly from the expression and phosphorylation of PAX3-FOXO1, we conclude that the acquisition of the oncogene is the initiating driver mutation in the development of ARMS.

Because the aneuploid state is detrimental to a cell, growth retardation is one of the first cellular responses \[[@R42], [@R43]\]. Therefore, in order for muscle cells to develop into ARMS, the cells containing the fusion protein must overcome this proliferative defect. Consistent with the cell\'s normal response to the aneuploid state, we saw changes in cell cycle regulatory genes that would be expected to inhibit cellular proliferation. However, we also found that the presence of the fusion protein *enhances* proliferation, which seems in direct contrast to altered cell cycle regulatory genes. This apparent contradiction can be explained by the fact that we also observed significant increases in the expression of growth factor related genes and proliferative transcription factors, several of which are known direct targets of PAX3-FOXO1 \[[@R20], [@R44]\]. Taken together, these results support the idea that the oncogenic fusion protein serves a second role as a driving mutation: it promotes the increased expression of growth factor related genes, either directly or indirectly through downstream effects, that are capable of negating the inhibitory changes in cell cycle regulatory proteins to override the growth retarding effects of the aneuploid state.

Based on the evidence presented here, we propose the following model by which PAX3-FOXO1 serves as the initial driving mutation in the development of ARMS (Figure [4](#F4){ref-type="fig"}). In this model myogenic cells in situ randomly and somatically acquire the t(2;13)(q35;q14) translocation, an event which is mimicked in our *in vitro* model system through the stable transduction of primary myoblasts. The subsequent expression of PAX3-FOXO1, maintained over repeated cellular duplications either in situ or *in vitro*, will bind to select promoters and regulatory sequences, thereby directly altering the expression of a subset of genes (Table [1](#T1){ref-type="table"}, carats). These alterations could then initiate a cascade of indirect downstream events resulting in a global alteration of gene regulatory networks that ultimately reprogram proliferating myoblasts. This reprogramming results in the disruption of multiple aspects that lead to aneuploidy, including maintenance of the segregation machinery, regulation of chromosome segregation, promotion of chromosome cohesion and condensation, and insuring proper progression through mitosis.

In response to the aneuploid state, the cells attempt to halt proliferation, which is evidenced through our observed changes in the expression of cell cycle regulatory genes and miRNAs, and which most likely result from the aneuploid state and not from direct involvement of the fusion protein. However, PAX3-FOXO1 directly induces the expression of multiple and redundant proliferative genes, including growth factors, growth factor receptors, and proliferative transcription factors (Table [2](#T2){ref-type="table"}, carats), thereby overriding aneuploidy-induced proliferation defects. Finally, the cells must be able to acquire a tolerance to the aneuploid state, most likely by affecting genes important in p53 regulation, in order to promote ARMS progression.

We reported that PAX3-FOXO1 is phosphorylated at Ser201 by GSK3β and small molecule inhibitors of this enzyme not only reduce phosphorylation at this site but also attenuate ARMS tumor phenotypes \[[@R26]\]. Consistent with this work, and adding to our present model, we found that phosphorylation contributes to the PAX3-FOXO1-dependent changes in gene and miRNA expression leading to the acquisition and persistence of aneuploidy. We found that although inhibiting phosphorylation of PAX3-FOXO1 at Ser201 and Ser205 did not affect aneuploidy, it altered the severity of chromosomal structural abnormalities (Figure [1](#F1){ref-type="fig"} and Table [3B](#T3b){ref-type="table"}) and blocked the enhanced proliferation of primary myoblasts (Figure [2](#F2){ref-type="fig"}). We found phosphorylation contributes to the altered expression of multiple genes and miRNAs, which was evidenced by the reversion of gene expression to levels equivalent to the negative control in cells stably expressing phospho-incompetent mutants (Figure [3](#F3){ref-type="fig"}). Therefore, our results provide additional evidence to support the role post-translational modifications make in regulating the contributions of an oncogene to the development of a solid tumor. Further, these results identify this event, the specific phosphorylation of PAX3-FOXO1, as a viable biological target for therapy development (Figure [4](#F4){ref-type="fig"}). Interestingly, inhibition of phosphorylation at Ser209 enhanced the severity of sister chromatid dissociation (Figure [1D](#F1){ref-type="fig"} and Table [3B](#T3b){ref-type="table"}), and had proliferation rates indistinguishable from the negative control (Figure [1](#F1){ref-type="fig"}). Although we previously reported undetectable levels of phosphorylation of PAX3-FOXO1 at Ser209 in this system \[[@R28]\], the results presented here would suggest that this event does occur at greatly reduced levels and below the limits of detection.

The results presented here are important for directing the development of new therapies for the treatment of ARMS (Figure [4](#F4){ref-type="fig"}) and provide implications for how others may approach the development of therapies for solid tumors. Many present experimental therapies for ARMS, and other solid tumors, focus on inhibiting a single gene or a single pathway genetically located downstream of the oncogene. However, these therapies have not proven effective in Phase I or Phase II clinical trials for ARMS \[[@R45]--[@R48]\]. These outcomes are not surprising given the global nature of mRNA and miRNA alterations seen in cells that express PAX3-FOXO1. As such, therapies targeting a single gene product or pathway would be expected to have limited efficacy since multiple genes with similar biological functions could easily compensate.

![Model describing the role of PAX3-FOXO1 in the development of ARMS and how it informs potential therapy development](oncotarget-07-62814-g004){#F4}

Therefore, we propose the development of a multi-faceted regimen that targets genetic or biological characteristics identified from our work. We published that small molecules such as LiCl attenuate ARMS tumor phenotypes \[[@R26]\]. Others demonstrated that compounds that interfere with growth factor dependent proliferation, such as Cixutumumab \[[@R48]\], or the survival of aneuploid cells, such as chloroquine \[[@R49]\], might be effective as new treatments for human solid tumors. Therefore, we propose a combination therapy that minimally utilizes these three drugs for the treatment of ARMS. This regimen is expected to target both the driver mutation, with LiCl or other GSK3beta inhibitors preventing the phosphorylation of PAX3-FOXO1 at Ser201 \[[@R26]\] thereby inhibiting altered gene expression and the biological consequences of this driver mutation, with chloroquine killing aneuploid cells while Cixutumumab removes the growth-factor-dependent proliferative advantage. This regimen is expected to be specific for ARMS tumor cells, since all targets derive from the presence of the unique genetic mutation, have minimal negative effects since all proposed drugs are proven safe in human subjects, and would inhibit three molecular events essential for the viability of ARMS tumor cells.

Finally, the paradigm created here has implications that may be applied to other tumor models. Studies are being published with more frequency that utilize deep-sequencing strategies to examine global gene and miRNA expression changes resulting from the presence of an oncogene or the process of malignant transformation for examples see \[[@R50]--[@R53]\]. Often a single gene, miRNA, or miRNA locus is selected from these global studies for more in depth investigation to utilize as a specific target for therapy development. However, given that our results demonstrate that individual tumor phenotypes (e.g., induction of aneuploidy) arise from alterations in multiple biological aspects of this phenotype (e.g., mitotic progression, segregation machinery, etc.), it would be expected that a cell would be capable of compensating for the therapeutic inhibition of a single gene or miRNA. Therefore, as illustrated in the present study, deep sequencing studies should be utilized to discover how global gene regulatory alterations affect biological phenotypes and then use this knowledge to develop a multi-faceted therapeutic approach to target specific aspects of multiple different tumor phenotypes that are essential for the progression of the disease.

MATERIALS AND METHODS {#s4}
=====================

Primary cells and culture conditions {#s4_1}
------------------------------------

Mouse primary myoblasts were isolated from 2 - 4 day old C57/Bl6 mice as previously described \[[@R40]\]. Cells were grown as previously described \[[@R25]--[@R28], [@R40]\] and were passage-matched to prevent possible differences due to passage conditions.

Stable transduction of primary myoblasts {#s4_2}
----------------------------------------

Mouse primary myoblasts were stably transduced as previously described \[[@R24], [@R40]\] with the MSCV-IRES-puromycin empty vector, vector containing FLAG epitope-tagged Pax3 (FLAG-Pax3), FLAG-PAX3-FOXO1, or FLAG-PAX3-FOXO1 in which each of the previously identified phosphorylation sites \[[@R27], [@R28]\] were mutated to the phospho-incompetent alanine (S201A, S205A, or S209A) \[[@R27], [@R28]\]. Three days post-transduction, cells were selected using puromycin, as previously described \[[@R28]\]. The stably transduced cells were harvested and pooled from three independent transductions to create a single population that express each construct.

Western blot analysis {#s4_3}
---------------------

Stably transduced cells were grown to 80% confluency, harvested, and total cell extracts made, as previously described \[[@R26]--[@R28], [@R40]\]. Equal amounts of total cell lysates (12μg) were separated by 8% SDS-PAGE and analyzed by Western blot analysis using antibodies specific for Pax3 \[[@R54]\] as previously described \[[@R27], [@R28]\].

Metaphase chromosome analysis {#s4_4}
-----------------------------

Transduced primary myoblasts were grown until logarithmic phase growth (approximately 70 - 80% confluency). The cells were then treated with Colcemeid (100ng/ml), harvested, and prepared for metaphase chromosome analysis, as previously described \[[@R55]\]. Metaphase images were captured using an Applied Imaging Model ER-3339 cooled CCD camera (Applied Spectral Imaging) mounted on top of a Nikon Eclipse E400 with CytoVision version 3.1 image-capture software (Applied Spectral Imaging).

RNA extraction, cDNA library construction, and cDNA deep sequencing {#s4_5}
-------------------------------------------------------------------

Primary myoblasts stably expressing empty vector, FLAG-PAX3, or FLAG-PAX3-FOXO1 were grown to approximately 80% confluency. Total RNA was isolated using the miRNeasy mini kit (Qiagen), allowing for the isolation of RNA \<30 bp in length, according to the manufacturer\'s specifications. Poly-A^+^ mRNA or miRNA were isolated from 4μg total RNA, to generate the respective cDNA libraries, both using the Illumina sample preparation kits according to the manufacturer\'s specifications. The cDNA libraries were provided a unique index identifier, allowing the clustering of several samples into a single sequencing lane, and deep sequencing analyses were performed in triplicate from three independent cell growth, RNA isolation, and cDNA library constructions.

mRNA-seq data analysis {#s4_6}
----------------------

The raw data was groomed and trimmed for quality of read using online Galaxy analysis ([https://usegalaxy.org](https://usegalaxy.org/)), resulting in 40 - 41 high quality base pair reads for each sequence with between 4 - 6 million independent reads for each sample. The sequences were mapped to the mouse genome using Tophat analysis, transcripts were assembled using the Cufflinks program, and individual replicates were merged into a single file using Cuffmerge. The resulting transcript reads were normalized using Fragments Per Kilobase of transcript per Million mapped reads (FPKM) analysis, which normalizes each identified sequence for the length of the identified transcript and the volume of the total read yield from each run. Differential expression was determined from these normalized values using the Cuffdiff program, which not only compares differential expression of the merged files between sets but also utilizes the sequence results from the three independent determinations within each set to assign statistical significance to the differential expression.

miRNA-seq data analysis {#s4_7}
-----------------------

Raw fastq sequences were obtained from the Illumina Genome Analyzer II using the "Demultiplex" algorithm in the CASAVA 1.8.2 software (Illumina) that allows the identification of individual samples by "index sequences" contained within the adapters and introduced during the adapter ligation and amplification of the samples. miRNAKey, a software package used for analyzing small RNA data obtained from deep sequencing experiments, was used for data analysis at default settings. The pipeline clips the Illumina 3′ adaptor sequences from the reads, maps the clipped reads to miRBase and uses the Seq-EM algorithm to estimate the distribution of multiply mapped reads across the observed miRNAs. Sequences less than 16 bases after adaptor clipping were removed. The read counts obtained were then used for differential expression analysis between control and experimental samples using EBSeq from the R package with a False Discovery Rate (FDR) of 5%. We used the default 'Median Normalization' in EBSeq to make the counts comparable across samples.

Proliferation assay {#s4_8}
-------------------

The proliferation rate of cells stably expressing empty vector, FLAG-PAX3, FLAG-PAX3-FOXO1, or the phospho-incompetent mutants was assessed using the CCK-8 colorimetric assay kit, according to the manufacturer\'s specifications (Cell Counting Kit-8, Dojindo Molecular Technologies) and as previously described \[[@R26]\].

qRT-PCR {#s4_9}
-------

Total RNA was extracted from cells stably expressing empty vector, FLAG-PAX3, FLAG-PAX3-FOXO1, or the FLAG-PAX3-FOXO1 phospho-mutants. Equal amounts of isolated RNA (100ng) were used for cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad) for mRNA and the Taqman miRNA reverse transcription kit (Applied Biosystems) for miRNA. The qRT-PCR was performed on the resulting cDNA using the CFX96 Touch™ Real-Time PCR Detection System using commercially available primer/probe sets and the Applied Biosystems Universal Master Mix, according to the manufacturer\'s specifications. All results were normalized for GAPDH (mRNA) or the U6 small nuclear RNA for miRNA and reported as fold expression relative to the results obtained for cells stably transduced with the empty vector.

SUPPLEMENTARY FIGURES AND TABLES {#s5}
================================

All deep sequencing was performed in the LCRC Translational Genomics Core facility.
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